Name | Number of supported studies | Average coverage | |
---|---|---|---|
ciliated cell | 14 studies | 30% ± 9% | |
astrocyte | 12 studies | 32% ± 15% | |
endothelial cell | 8 studies | 31% ± 15% | |
glutamatergic neuron | 8 studies | 46% ± 27% | |
oligodendrocyte precursor cell | 8 studies | 32% ± 13% | |
fibroblast | 8 studies | 20% ± 6% | |
GABAergic neuron | 7 studies | 48% ± 22% | |
neuron | 6 studies | 31% ± 13% | |
epithelial cell | 6 studies | 27% ± 10% | |
oligodendrocyte | 6 studies | 27% ± 9% | |
interneuron | 5 studies | 53% ± 21% | |
mast cell | 5 studies | 20% ± 5% | |
endothelial cell of lymphatic vessel | 5 studies | 19% ± 3% | |
retina horizontal cell | 4 studies | 24% ± 2% | |
retinal cone cell | 4 studies | 19% ± 4% | |
granule cell | 3 studies | 29% ± 2% | |
microglial cell | 3 studies | 25% ± 10% | |
pericyte | 3 studies | 31% ± 17% | |
retinal rod cell | 3 studies | 23% ± 4% | |
abnormal cell | 3 studies | 22% ± 7% | |
connective tissue cell | 3 studies | 20% ± 4% | |
goblet cell | 3 studies | 29% ± 10% | |
adipocyte | 3 studies | 26% ± 4% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2379.46 | 1444 / 1445 | 99% | 12.15 | 182 / 183 |
brain | 100% | 3761.44 | 2633 / 2642 | 99% | 18.45 | 696 / 705 |
breast | 100% | 3146.61 | 459 / 459 | 96% | 16.78 | 1077 / 1118 |
intestine | 100% | 3302.46 | 965 / 966 | 96% | 9.15 | 508 / 527 |
lung | 100% | 2552.40 | 576 / 578 | 97% | 10.94 | 1115 / 1155 |
stomach | 100% | 2079.20 | 359 / 359 | 96% | 9.26 | 275 / 286 |
pancreas | 99% | 1531.02 | 326 / 328 | 96% | 9.82 | 171 / 178 |
skin | 100% | 2980.06 | 1806 / 1809 | 96% | 14.55 | 451 / 472 |
thymus | 100% | 5285.10 | 653 / 653 | 95% | 14.44 | 574 / 605 |
kidney | 100% | 2638.28 | 89 / 89 | 93% | 9.67 | 834 / 901 |
prostate | 100% | 3859.07 | 245 / 245 | 92% | 11.67 | 461 / 502 |
bladder | 100% | 3559.38 | 21 / 21 | 92% | 9.15 | 462 / 504 |
adrenal gland | 100% | 3797.97 | 258 / 258 | 91% | 17.05 | 210 / 230 |
ovary | 100% | 4860.90 | 180 / 180 | 90% | 9.42 | 386 / 430 |
uterus | 100% | 4806.78 | 170 / 170 | 90% | 10.40 | 412 / 459 |
adipose | 100% | 2624.41 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 2569.02 | 241 / 241 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 2541.70 | 1333 / 1335 | 0% | 0 | 0 / 0 |
muscle | 95% | 1388.73 | 762 / 803 | 0% | 0 | 0 / 0 |
heart | 94% | 2132.07 | 807 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 8.88 | 40 / 45 |
liver | 56% | 512.73 | 127 / 226 | 31% | 2.07 | 124 / 406 |
eye | 0% | 0 | 0 / 0 | 84% | 6.51 | 67 / 80 |
lymph node | 0% | 0 | 0 / 0 | 76% | 7.35 | 22 / 29 |
peripheral blood | 47% | 1150.84 | 436 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006325 | Biological process | chromatin organization |
GO_0051260 | Biological process | protein homooligomerization |
GO_0006303 | Biological process | double-strand break repair via nonhomologous end joining |
GO_0051091 | Biological process | positive regulation of DNA-binding transcription factor activity |
GO_0045830 | Biological process | positive regulation of isotype switching |
GO_0006974 | Biological process | DNA damage response |
GO_0097680 | Biological process | double-strand break repair via classical nonhomologous end joining |
GO_0071481 | Biological process | cellular response to X-ray |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_1990166 | Biological process | protein localization to site of double-strand break |
GO_2000042 | Biological process | negative regulation of double-strand break repair via homologous recombination |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0000077 | Biological process | DNA damage checkpoint signaling |
GO_0000776 | Cellular component | kinetochore |
GO_0005657 | Cellular component | replication fork |
GO_0005654 | Cellular component | nucleoplasm |
GO_0016604 | Cellular component | nuclear body |
GO_1990391 | Cellular component | DNA repair complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0000781 | Cellular component | chromosome, telomeric region |
GO_0035861 | Cellular component | site of double-strand break |
GO_0005634 | Cellular component | nucleus |
GO_0035064 | Molecular function | methylated histone binding |
GO_0042393 | Molecular function | histone binding |
GO_0042162 | Molecular function | telomeric DNA binding |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0140566 | Molecular function | histone reader activity |
GO_0061629 | Molecular function | RNA polymerase II-specific DNA-binding transcription factor binding |
GO_0002039 | Molecular function | p53 binding |
GO_0061649 | Molecular function | ubiquitin-modified histone reader activity |
GO_0005515 | Molecular function | protein binding |
GO_0003684 | Molecular function | damaged DNA binding |
Gene name | TP53BP1 |
Protein name | Tumor suppressor p53-binding protein 1 Tumor protein p53 binding protein 1 TP53-binding protein 1 (53BP1) (p53-binding protein 1) (p53BP1) |
Synonyms | |
Description | FUNCTION: Double-strand break (DSB) repair protein involved in response to DNA damage, telomere dynamics and class-switch recombination (CSR) during antibody genesis . Plays a key role in the repair of double-strand DNA breaks (DSBs) in response to DNA damage by promoting non-homologous end joining (NHEJ)-mediated repair of DSBs and specifically counteracting the function of the homologous recombination (HR) repair protein BRCA1 . In response to DSBs, phosphorylation by ATM promotes interaction with RIF1 and dissociation from NUDT16L1/TIRR, leading to recruitment to DSBs sites . Recruited to DSBs sites by recognizing and binding histone H2A monoubiquitinated at 'Lys-15' (H2AK15Ub) and histone H4 dimethylated at 'Lys-20' (H4K20me2), two histone marks that are present at DSBs sites . Required for immunoglobulin class-switch recombination (CSR) during antibody genesis, a process that involves the generation of DNA DSBs . Participates in the repair and the orientation of the broken DNA ends during CSR (By similarity). In contrast, it is not required for classic NHEJ and V(D)J recombination (By similarity). Promotes NHEJ of dysfunctional telomeres via interaction with PAXIP1 . . |
Accessions | ENST00000417342.1 H7C495 ENST00000434595.1 ENST00000382044.9 [Q12888-2] Q12888 C9JXV0 ENST00000450115.6 [Q12888-3] H7C151 ENST00000413546.1 ENST00000382039.7 H7C3N7 ENST00000467474.1 H7BZY0 ENST00000434561.1 A6NNK5 ENST00000263801.7 [Q12888-1] Q3YL84 M0R142 ENST00000411772.5 |